Johnson & Johnson Advances Atopic Dermatitis Treatment with Yellow Jersey Therapeutics Acquisition

Acquisition Details

Johnson & Johnson has announced the completion of its acquisition of Yellow Jersey Therapeutics, a subsidiary of Numab Therapeutics, in a transaction valued at approximately $1.25 billion. This acquisition secures global rights to NM26, a promising investigational bispecific antibody ready for Phase 2 trials in atopic dermatitis (AD).

NM26 and Its Potential

NM26 targets two clinically proven pathways, the IL-4R alpha subunit (IL-4Rα) and IL-31, which are responsible for Th2-mediated skin inflammation and itching, respectively. David Lee, Global Immunology Therapeutic Area Head at Johnson & Johnson Innovative Medicine, emphasized the significance of NM26, stating, "NM26 is designed to help different subpopulations of patients by targeting two disease-driving pathways, which is key when treating a heterogeneous disease like AD." This development is seen as a potential game-changer in the standard of care for AD and other inflammatory skin diseases involving Th2 inflammation and itch.

The Challenge of Atopic Dermatitis

Atopic dermatitis is the most common inflammatory skin disease, characterized by itching and inflammation exacerbated by scratching. The condition can lead to severe skin infections, pain, sleep disturbances, anxiety, stress, depression, and even an increased risk of suicide. According to Candice Long, Worldwide Vice President, Immunology at Johnson & Johnson, "Nearly three-quarters of people with AD are not achieving remission with currently available treatments. The unmet need is high, and we must do better for patients."

Johnson & Johnson's Commitment

Johnson & Johnson's investment in NM26 underscores its commitment to addressing the high unmet needs in AD treatment. The company aims to achieve durable, symptom-free remission for all patients living with immune-mediated diseases. As Long highlights, "Our investment in NM26, and other bispecific antibodies, is another important step towards our mission."

H5N1 Influenza in Dairy Cows

In a separate study published in Nature, researchers examined the H5N1 avian influenza virus in U.S. dairy cattle. The findings revealed that viruses derived from lactating dairy cattle induced severe disease in mice and ferrets when administered via intranasal inoculation. Although the virus bound to both avian and human-type cellular receptors, it did not efficiently transmit among ferrets exposed via respiratory droplets.

Highlights

• Johnson & Johnson acquired Yellow Jersey Therapeutics for $1.25 billion to secure rights to NM26.
• NM26, targeting IL-4Rα and IL-31, is poised to enter Phase 2 trials for atopic dermatitis.
• AD, the most common inflammatory skin disease, poses significant challenges, with current treatments failing to achieve remission for nearly 75% of patients.
• Johnson & Johnson is committed to developing treatments for durable, symptom-free remission in immune-mediated diseases.
• A study in Nature found that H5N1 avian influenza virus from dairy cows can induce severe disease but does not transmit efficiently among ferrets via respiratory droplets.